Ciba's Voltaren XR for chronic rheumatoid arthritis approved March 8.
Executive Summary
CIBA-GEIGY VOLTAREN-XR APPROVED FOR CHRONIC RHEUMATOID ARTHRITIS and osteoarthritis on March 8. The nonsteroidal anti-inflammatory extended-release tablet (NDA 20-254) was designated a "3S" by FDA, denoting a new formulation of an already marketed product given a standard review.